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Historical approaches to modeling psychiatric 
disorders
Psychiatric disorders constitute a diverse set of con­
ditions, variously impinging on all domains of mental 
function and affecting the most fundamental human 
attributes: language, thought, perception, mood and 
sense of self. Collectively, they cause a substantial public 
health burden, greater than cancers or cardiovascular 
disease [1]. The proportional burden is actually increasing 
as we learn more about the molecular bases of other 
common diseases and how to treat them, through the 
application of molecular genetics. Until recently, these 
approaches have been difficult in psychiatry as we have 
had few entry points to the underlying molecular 
mechanisms. This is now changing as psychiatric genetics 
reveals more and more specific mutations predisposing 
to psychiatric disease. These discoveries, along with revo­
lu tionary advances in neurogenetic techniques, provide 
the means to elucidate pathogenic mechanisms through 
modeling such mutations in animals and defining their 
effects at the neurobiological level.
In the absence of such information on specific genetic 
causes, previous modeling approaches for psychiatric 
disorders have been based either on surface similarities 
between behavioral assays in rodents and domains of 
psychopathology in humans or on dissecting the psycho­
pharmacological mechanisms of known drugs [2,3]. 
These have both centered on the goal of generating 
relevant behavioral assays that can provide platforms for 
drug screening.
The behavioral approach first defines behavioral assays 
in animals that are thought to mimic symptoms in 
particular psychological domains [4,5]. Thus, ‘learned 
helplessness’ is thought to model depressive symptoms, 
spontaneous alternation or latent inhibition are believed 
to index working memory, which is often deficient in 
schizophrenia, and decreased social interactions in 
rodents are thought to relate to similar effects in humans 
with autism. Animals can be generated with defects in 
any of these or similar domains by a variety of manipu­
lations, including pharmacological, surgical, experiential 
and genetic. The relevance (or predictive validity) of these 
models to human psychopathology has generally been 
tested by whether they are responsive to known 
medications, such as antidepressants or antipsychotics 
[3]. Using these approaches, it has been possible to 
generate a large number of such models, which have been 
used to screen through drug libraries for novel thera­
peutic compounds or to test prototypes of existing medi­
ca tion. Unfortunately, these approaches have yielded few 
new drugs [6,7].
There are several drawbacks to using only the criterion 
of response to known medication. First, most of the 
models do not have causal etiological validity ­ acute 
blockade of NMDA­type receptors for glutamate or 
ventral hippocampal lesion are not actual causes of 
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schizophrenia, for example. Second, the surface parallels 
between rodent and human behavior may be misleading. 
On the contrary, we should expect some of the underlying 
neurobiological defects to manifest at the behavioral level 
in species­specific ways, which may or may not appear 
related [2]. Third, defining predictive validity based on 
responsiveness to known drugs inevitably restricts the 
focus to mechanisms affected by those drugs. This 
circularity has undoubtedly contributed to the paucity of 
new drug mechanisms being found.
A complementary approach is now becoming possible 
as particular mutations causing psychiatric illness are 
being identified at an ever­increasing rate. Mouse 
models of these mutations can now be investigated 
using increasingly powerful and sophisticated tools to 
get at the underlying neurobiology and elucidate 
pathogenic mechanisms, from the level of synapses 
formed between specific cell types in specific circuits to 
the level of dynamic function of neuronal networks and 
concomitant moment­to­moment behavior. These types 
of approaches should provide the necessary neuro­
biological knowledge to enable the rational design of 
new therapeutics.
A revolution in psychiatric genetics
The field of psychiatric genetics is undergoing a profound 
paradigm shift. For several decades, the prevailing model 
has held that psychiatric disorders arise in any individual 
due to the cumulative effects of a large number of 
common variants [8­10]. Each of these, by themselves, 
would have a very small effect on risk, but when the 
collective burden of such alleles passes a putative 
threshold, the system would be pushed into a pathogenic 
state. Though this model has little empirical support, it 
provided the theoretical foundation for genome­wide 
association studies (GWAS) [11], which aim to detect 
such variants by comparing allele frequencies for millions 
of such variants between cases and controls [12­15]. For 
psychiatric disorders, these studies, now carried out on 
tens of thousands of people, have yielded a number of 
replicated common variants reaching the threshold for 
genome­wide significance [16­26]. These include eight 
loci for schizophrenia [26,27], two for bipolar disorder 
[25] and one for schizophrenia and bipolar disorder 
together [25]; three potential loci arising from individual 
GWAS for autism [22­24] have not yet been replicated on 
the same scale. These findings point to loci that may be 
involved in disease risk at a population level but do not 
identify or speak to the likely allelic frequency of causal 
variants [28]. Each of the associated variants has a tiny 
statistical effect on risk at the population level and, 
collectively, the significant single nucleotide polymorph­
isms statistically account for only a few percent of the 
overall heritability of the disorder [18,25,26].
The alternative model is that psychiatric disorders arise 
due to mutations in any of a very large number of genes 
[11,29­33]. Under this model, psychiatric diagnostic 
categories are actually umbrella terms for large numbers 
of distinct genetic disorders that happen to result in 
similar spectra of symptoms. This is the sort of genetic 
heterogeneity that underlies categories such as congenital 
deafness, epilepsy, mental retardation, retinitis pigmen­
tosa, many cancers and other conditions [34,35].
It has, of course, been known for some time that 
psychiatric illness could arise due to single mutations. 
Well­known examples include fragile X syndrome [36], 
Rett syndrome [37] and mutations in the neuroligin genes 
NLGN3 and NLGN4 [38], all of which are associated with 
autistic spectrum disorder, and velocardiofacial syndrome 
(22q11.2 deletion syndrome) [39] and the Scottish DISC1 
translocation [40], which are associated with schizo­
phrenia and other psychiatric diagnoses. The number of 
such identified mutations is now steadily and rapidly 
increasing, thanks to the application of new genomic 
microarray [41,42] and sequencing technologies [43,44], 
to the point where they collectively explain an appreciable 
fraction of psychiatric diagnoses.
Copy number variants (deletions or duplication of 
chromosomal segments, often affecting multiple genes) 
have been most readily identified and make up an impor­
tant class of causal mutations in schizophrenia [42,45­51], 
autism [41,52­54], attention deficit­hyper activity disorder 
[55­58], Tourette syndrome [59], developmental delay 
and mental retardation [60,61], epilepsy [62] and cortical 
malformations [63]. Whole­exome and whole­genome 
sequencing approaches are now also identifying large 
numbers of point mutations individually responsible for 
psychiatric conditions [64­71].
A number of important principles have emerged from 
these studies. First, there is considerable overlap in the 
genetic etiology of what had previously been considered 
distinct disorders. Individual mutations that predispose 
to one class of psychiatric illness, such as schizophrenia, 
are also associated with other disorders, such as bipolar 
disorder, autism, mental retardation, epilepsy, attention 
deficit hyperactivity disorder and Tourette’s syndrome 
(for example, [31,72­77]), in agreement with recent epi­
demio logical data indicating shared risk [78­83]. 
Traditional diagnostic categories, although still very 
useful in organizing daily practice in psychiatry, may 
therefore represent not natural kinds in terms of etiology, 
but more or less distinct phenotypic endpoints that may 
arise from common origins.
Second, the mutations so far discovered are charac­
terized by incomplete penetrance and variable expres­
sivity [31,77,84]. As with the DISC1 translocation, such 
mutations may result in a range of phenotypes and many 
carriers may be unaffected by any psychiatric condition 
Mitchell et al. BMC Biology 2011, 9:76 
http://www.biomedcentral.com/1741-7007/9/76
Page 2 of 13
[85]. Of course, the penetrance depends on which pheno­
type is being assessed ­ it will be lowest for specific 
diagnoses, higher for psychiatric illness generally and 
higher still for neurobiological endophenotypes, which 
may be apparent even in clinically unaffected carriers.
Third, many of the identified genes are involved in neural 
development [42,77,86]. While certainly not exclu sive, this 
is probably the largest category of suscep tibility genes. 
Genes involved in activity­dependent synaptic plasticity, 
such as FMR1, are also highly represented. With increasing 
numbers of genes being identified all the time, it is 
becoming possible to assign many of them to specific 
biochemical pathways or cellular processes, such as 
synapse formation and plasticity (for example, [64,66,87­89]).
Fourth, allelic specificity and dosage are extremely 
important. Different mutations in the same gene may 
result in very different phenotypic outcomes. As a classic 
example, Duchenne muscular dystrophy and Becker’s 
muscular dystrophy are caused by different types of 
mutations in the dystrophin gene: their clinical severity, 
manifestation, and age of onset are also different [90]. 
Similar effects are seen for genes implicated in neuro­
logical and psychiatric disorders [32,35], as described 
later. In addition, some alleles may cause severe neuro­
logical disorders when homozygous but manifest as 
psychiatric illness in heterozygous form [32,35,91].
Fifth, while these findings highlight the importance of 
rare single mutations, they do not necessarily imply a 
simple mode of inheritance. Many of the mutations 
found so far show a dominant effect, but recessive muta­
tions are likely to also contribute a sizeable fraction of 
cases [71,92]. In addition, there is likely to be an impor­
tant role for modifying mutations in the genetic 
background that can alter the phenotypic expression of 
the ‘primary’ mutation. This is the norm, even for the 
most classically ‘Mendelian’ disorders [35,77,93]. One 
should thus expect a distribution of genetic mechanisms 
across cases ­ some will be caused by highly penetrant 
mutations, others by mutations with more variable out­
come, which are modified to some extent by the genetic 
background, and yet others will involve the inheritance of 
two or more distinct mutations [35,77,94­96].
Sixth, the eventual phenotype will also be modified by 
non­genetic factors, including (i) intrinsic developmental 
variation, where the phenotypic outcome varies due to 
inherent noise in the molecular processes mediating 
neurodevelopment [97], and (ii) environmental risk 
factors, which have been implicated by epidemiological 
studies. For schizophrenia, for example, these include 
maternal infection, urbanicity, migration and cannabis 
use [98]. The impact of such factors in individuals may be 
highly uneven and dependent on genotype.
Despite these complexities, the major finding is clear: 
mutations with large effect on risk of psychiatric 
disorders exist and we now have the means to identify 
them. If we think of this as a genetic screen for mutations 
causing a specific phenotype, with demonstrated satura­
tion mutagenesis of the human population [32], then the 
most effective approach to follow up these discoveries is 
clear: find the mutations of largest effect and use these as 
entry points to elucidate the underlying biology.
Bone fide models of genetic etiology
Advances in genetic engineering allow us to recapitulate 
human mutations in mice, and increasingly in rat. It is 
possible to generate animals with full gene knock­outs, 
conditional removal of the gene with spatial and temporal 
control, knock­in of exact human alleles, and to precisely 
engineer genomic deletions or duplications into syntenic 
regions of mouse chromosomes, thereby yielding animal 
models with direct construct validity; that is, where the 
manipulation is an actual cause of the condition in 
humans [99,100]. An emerging principle is the impor­
tance of allelic specificity for phenotypic outcome. For 
example, mouse mutants of Nlgn3 and Shank3 that 
recapitu late human alleles found in autism patients 
demon strate selective effects that differ from null alleles 
[101­103]. Mice modeling human deletions or duplica­
tions can also be generated [104­106], and phenotypically 
compared with mutations of single genes in the affected 
regions in order to track down the specific culprits 
[107,108].
The number of models generated to date that directly 
recapitulate or mimic the effects of human alleles is 
small, but they have already begun to reveal details of the 
mechanisms of pathogenesis in specific mutants and to 
highlight convergent pathways, as well as some important 
general principles. For example, mutations in Nlgn, Nrxn 
(encoding a neurexin), Shank3 (encoding an adaptor 
protein that interacts with the cytoplasmic tails of Nlgn 
proteins) and Cntnap2 (which also encodes a member of 
the neurexin protein family) all affect synapse formation, 
altering the biochemical composition of synapses and the 
balance between excitation and inhibition between 
specific cell types in developing neuronal networks, with 
a range of concomitant behavioral deficits [101­103,109­
112]. Local and long­range circuitry can also be altered 
by defects in cell migration and axon projection, which 
have been observed in DISC1 mutants or transgenic lines 
(for example, [113,114]), paralleling observations in 
humans with DISC1 mutations [115]. Alterations in long­
range functional connectivity have also been observed ­ 
for example, between cortex and striatum in Shank3 
mutant mice [111], between cortex and hippocampus in 
Df(16)A+/- mice, which recapitulate 22q11.2 deletion 
[105], and in cortical synchrony in Cntnap2 mutant mice 
[112]. These kinds of observations help generate specific 
hypo theses regarding the cellular origins of 
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pathophysiological states, which can now be tested with 
the increasingly sophisticated neurogenetic tools avail­
able (for example, [116­118]).
Studies in some animal models, such as mice mutant in 
Fmr1 or MeCP2 (the gene for methyl CpG binding protein 
2, mutated in Rett syndrome), have even suggested 
possible new therapies based on detailed understanding 
of the biochemical pathology [119­121]. Despite all these 
advances, however, the complete path ways of patho­
genesis for any single case remain obscure. Even for 
Fmr1, where the effects of mutation of this gene on 
synaptic plasticity are well described at the biochemi cal 
and cellular levels, the ultimate impact of these changes 
on the functions of specific neural circuits and how these 
explain the observed behaviors or psycho pathology are 
only beginning to be unraveled [122].
To fully elucidate the pathogenic mechanisms for any 
specific mutation will require the integration of analyses 
across multiple levels, from protein function to systems 
neuroscience. What are the biochemical functions of the 
mutated protein? What are the cellular effects in various 
brain regions? How do these affect the function of 
various neural circuits? How do changes in neural activity 
play out over subsequent activity­dependent develop­
ment? What are the cascading or reactive consequences 
as the brain develops with these initial alterations? What 
are the concomitant effects on physiology and behavior? 
Which circuit defects are responsible for which behavioral 
phenotypes? Which are the ones most relevant to the 
symptoms of the human disease? Which are the ones 
most amenable to intervention? These are formidable 
challenges even in light of the spectacular advances in 
modern neuroscience.
Rather than predefining which areas or mechanisms 
are important or how we expect animal models of 
psychiatric disorders to behave, we can take a bottom­up 
approach and simply ask, for any of these mouse mutants 
‘what happens to their brain circuits?’ In analyzing the 
effects of any particular mutation it will be essential to 
consider the full cellular complexity of the circuitry and 
to use all the tools of modern molecular neuroscience to 
dissect the causal chains from primary genetic lesion to 
ultimate phenotype(s).
A cell type-based approach is key to link 
genes and circuits in discovering pathogenic 
mechanisms
Is there a generally useful strategy to tackle the problem 
of circuit pathogenesis in rodent models? If genes are the 
entry points to the cause and genetic architecture of 
psychiatric disorder, then we suggest that specific cell 
types may be the next set of entry points in neurobiology 
studies that may coherently link different levels of 
analysis, integrate different approaches and technologies, 
and yield useful answers in understanding pathogenic 
mechanisms. This is based on the following three first 
principles: individual cell types are the basic components 
of neural circuit organization, the building blocks of 
circuit assembly, and the basic units of gene expression 
and regulation in the brain (Figure  1). Therefore, a 
research program centered around cell type­based 
approaches is likely to be most productive in discovering 
the biological processes that build and operate neural 
circuits, and in revealing how these processes are altered 
by mutations and environmental insults.
The focus on cell types embraces the importance of 
different types of synapse. For example, mutations in 
Nlgn genes differentially affect the activity­dependent 
stabilization of excitatory (Nlgn1) or inhibitory (Nlgn2) 
synapses, selectively altering levels of different neuro­
trans mitter receptors [123­125]. The effect of Nlgn2 
muta tion is specific for inhibitory synapses from fast­
spiking (parvalbumin­positive) but not from somatostatin­
positive interneurons [126]. Such effects can also be 
region­specific: Nlgn3 knock­in mice show increased 
synaptic inhibition in the cortex, but increased excitatory 
synaptic transmission in the hippocampus [102]. 
Mutations in other genes, such as Fmr1 [122] and ErbB4 
or Nrg1 [127], show similarly cell type­ and synapse type­
specific effects. Understanding the particular profile of 
effects across multiple cell types in each mutant thus 
requires engagement with the cellular complexity of 
these circuits. This profile will also importantly include 
compensatory changes that may be secondarily induced 
and that could play important roles in pathogenesis (for 
example, [128­131]).
However, cell type­based analysis of neural circuits, 
although more routinely practiced in invertebrate 
systems, is highly challenging in the mammalian brain 
circuits, which consist of highly diverse and intermingled 
cell types that, until recently, could not be readily identi­
fied and experimentally accessed.
Fortunately, our ability to carry out such cell type­
based analyses is rapidly increasing, as new neurogenetic 
tools are developed. Gene expression profiles that define 
many cell types have been elucidated, enabling researchers 
to isolate specific genetic elements that can be used to 
drive cell type­specific expression of a variety of 
transgenic constructs with different uses. These include 
tracing axonal projections and synaptic connec tions, 
monitoring electrical activity, and non­invasively 
activating or shutting off neurons in behaving animals 
with optical methods or chemical ligands [117,132,133]. 
Combined with advances in multi­photon imaging, auto­
mated microscopy and computational resources to deal 
with very large datasets, these tools confer unprecedented 
power to dissect the structure and function of neuronal 
circuits [134,135].
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The Cre­loxP system has been adopted as a standard­
ized approach in the mouse to drive such constructs in 
specific cell types [136]. This binary gene expression 
system is an effective strategy that confers cell type 
specificity as well as combinatorial power. A Cre driver 
mouse line provides a ‘genetic switch’ in a cell type that, 
through site­specific recombination between loxP 
recognition sites, can turn on or off the various molecular 
probes that allow these cells to be analyzed by all the 
above modern techniques in their native circuit in vivo. 
An increasing number of Cre drivers thus will allow more 
systematic and integrated analysis of different cell types 
in the relevant circuits (for example, [137,138]). Further­
more, certain Cre drivers allow tracking the develop­
mental history of cell types, thereby enabling a compre­
hensive analysis of these cell types, from their specifica­
tion, migration and synapse development to their 
integra tion and function in the circuits. This approach 
will be particularly powerful in revealing how the 
developmental trajectories of cells and circuits are 
altered, what are the primary cell autonomous changes 
due to ‘direct hit’ of the mutant gene, and what are the 
secondary, possibly maladaptive changes that lead to 
aberrant circuit­level operations. Genetic tracking of the 
development of distinct cell types thus will begin to link 
studies of circuit assembly and function and their 
alterations in disease models. This can be achieved simply 
by bringing the Cre driver allele and relevant reporter 
alleles into an etiology model through breeding.
Analysis of multiple circuits brain­wide in a disease 
model will allow a more unbiased ‘screen’ for deficits, less 
restricted by prior knowledge and assumptions of disease 
pathology. This will allow definition of the overall profile 
of deficits across multiple systems in each individual 
mutant, which may be quite unique. Comparison of 
multiple disease models promises to identify shared or 
distinct circuit deficits in these models, which may 
underlie their shared or distinct behavioral phenotypes. 
To achieve this, it will be increasingly useful to establish 
high­throughput methods to effectively screen for 
alterations in cell numbers, connectivity, and function 
with cell type resolution [134].
The convergence of phenotype across multiple animal 
models may arise at the biochemical or cellular level in 
some cases (such as pathways involved in synapse forma­
tion [87,88] or in cAMP signaling [139]), but only at the 
level of the emergent functions of large­scale neuronal 
networks in others (such as the responsiveness of the 
dopaminergic system [129,140] or GABAergic signaling 
and neuronal synchrony in the prefrontal cortex [131]). A 
central challenge in this framework is thus to link the 
cellular level analysis of phenotypic effects on microcircuit 
Figure 1. A framework to elucidate pathogenic mechanisms from mutations to mental illness. The effects of mutations in different genes can 
be analyzed across development on diverse cell types, local circuit organization and emergent properties, functional connectivity on a macro scale 
and correlated behavior in animals or psychopathology in humans.
AssemblyPathogenesis
Development
Circuits
Cell types
Pathophysiology
Physiology
Genes
Behavior
Mutations
Evolution
Mental illness
Mitchell et al. BMC Biology 2011, 9:76 
http://www.biomedcentral.com/1741-7007/9/76
Page 5 of 13
architecture to the functional consequences for brain 
function on a larger scale. It is these emergent functions 
that will best explain behavior or psychopathology. 
Rather than merely demonstrating that a mouse mutant 
shows some patterns of behavior reminiscent of human 
symptomatology, it will be essential to analyze physio­
logical measures of circuit dynamics that explain 
behavior on a moment­to­moment basis in the relevant 
social and cognitive context.
Large-scale analysis of circuits that subserve 
behavior
The neuroscience of animal and human behavior has 
witnessed a productive paradigm shift in the past decade 
where the trend of assigning complex traits to single 
genes has given way to the realization that dynamic 
coordination between micro and macro circuits is key to 
understanding the neuronal basis of behavior [141]. In 
other words, the emphasis has shifted from associating a 
behavior to a single gene or its protein product simply 
because mutation of that gene disrupts that behavior to 
understanding how functional variability at the gene or 
protein level influences the dynamic coordination of 
neurons in systems that support a certain behavior.
In the context of schizophrenia, the approach has been 
descriptive and mechanistically naive in that, for the 
most part, it has focused on associating a common allelic 
variation, which in some cases has not even been asso­
ciated with a functional alteration, to complex behavioral 
disruptions whose physiology is still not fully understood. 
It is now increasingly being appreciated that a mecha­
nistic understanding of the pathophysiology of schizo­
phrenia is contingent upon (i) a better understanding of 
the dynamic coordination of neuronal processes that 
serve the behaviors that are disturbed in at least some 
cases of schizophrenia and (ii) understanding the 
functional role of implicated genes in micro and macro 
neuronal circuits that subserve this physiology. Recent 
studies, highlighted below, are beginning to make con­
siderable advances in these two approaches.
Electrophysiological recordings using electroencepha­
lo graphy (EEG) have for decades reported behaviorally 
relevant oscillatory activity throughout the cerebral 
cortex [142]. Until recently, however, these data did not 
receive much attention in the context of psychiatric dis­
orders, mostly because these measures had poor spatial 
and temporal resolution and were therefore considered 
functionally vague. The advent of magnetoencephalo­
graphy (MEG) and development of better EEG instru­
men tation combined with invasive electrophysiological 
recordings in laboratory animals has now provided 
strong evidence that these measures are biologically 
meaningful correlates of behavior [143]. This has been in 
part because of a series of elegant studies in animals 
establishing a relationship between single neuron activity 
and local field potential oscillations in behaviorally 
relevant contexts [144,145].
Animal studies have further demonstrated that 
synchronized neuronal oscillations at various frequencies 
are a measure of coordinated neuronal activity that 
supports behavior. EEG and MEG studies in humans have 
subsequently established a close relationship between 
oscillations at various frequencies and behavioral 
performance, including working memory and selective 
attention [146]. This has been followed by several studies 
reporting changes in neuronal oscillations associated 
with cognitive deficits as well as some symptoms of 
schizophrenia [147­150]. EEG and MEG are thus 
promising translational methods that assess oscillatory 
activity with similar temporal and spatial resolution to 
more invasive methods that can be used in behaving 
animals, as described later.
Thus, experimental procedures such as pharmaco logi­
cal and genetic manipulations can be applied in conjunc­
tion with single unit recording and local field potentials 
to understand the molecular and cellular processes that 
could contribute to abnormal oscillatory activities 
[151,152]. The emergent properties of neuronal networks 
depend crucially on the cellular architecture of the 
micro circuits involved and on the interactions between 
definable cell types. For example, the connectivity between 
parvalbumin­positive interneurons and pyramidal neurons 
is essential to drive oscillations in the gamma frequency, 
for phase­locking between rhythms at differ ent fre­
quencies and for long­range temporal coherence between 
brain areas, which subserves cognitive and perceptual 
functions [116,151,153­157]. Other interneuron subtypes 
have dissociable functions on neural systems [158­161].
The proliferation of cell type­specific genetic drivers 
and development of optogenetic approaches also enable 
follow­up experiments to directly test hypotheses arising 
from studies of mutant phenotypes by manipulating the 
activity of the implicated cell types in highly specific ways 
[117]. Such approaches should allow the field to move 
beyond correlations between various anatomical and 
physio logical disturbances in mutant animals to direct 
tests of how the precise connectivity patterns and 
strengths between different cell types affect the infor­
mation­processing parameters of microcircuits and larger 
neuronal networks and impact on specific behaviors 
[116,118,154,162].
While mice are likely to continue to lead the way in the 
discovery of the effects of specific mutations on nervous 
system development and function, we can also expect the 
increasing use of genetically manipulated rat and primate 
models to further dissect pathophysiological mecha­
nisms. Zinc­finger nucleases can be used to specifically 
modify the genome in effectively any type of cell, 
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including embryonic stem cells or early embryos, thus 
generating genetically modified organisms [163]. This 
approach has been used to generate gene knockouts 
[164] and also to knock in specific alleles in the rat 
[165,166], opening up the possibility of recapitulating 
human alleles in this species and others in the future. 
Brain cells can also be genetically modified in a cell type­
specific manner by viral transfection [132,167], making 
them accessible to acute gene manipulations and also to 
optogenetic techniques in any species, including rats and 
non­human primates [168,169]. These species, which 
have a much richer tradition of systems neuroscience and 
greater cognitive sophistication than the mouse, will no 
doubt be essential in further elucidating general princi­
ples and mechanisms of pathophysiology and relating 
them to humans.
Translation to humans
Because diagnostic classification of mental illnesses in 
clinical psychiatry at present is merely based on 
phenomenology and not disease etiology, it is important 
to consider translation between humans and rodent 
models not via clinical diagnosis but specific biological 
traits. These traits would include behavioral constructs 
and physiological characteristics, and are crucial in 
understanding disease mechanisms in rodent models. 
Even more importantly, such characteristics can be used 
as indicators of drug screening in rodents and markers in 
clinical trials with humans.
A major confound in analyzing neurobiological inter­
mediate phenotypes in psychiatric patients has been the 
extreme underlying (and previously cryptic) genetic 
hetero geneity. As the genetic factors involved in 
psychiatric illness are determined in more and more 
patients, it should be possible to make much more direct 
and powerful comparisons of underlying phenotypic 
traits between genetically defined subsets of humans and 
mice carrying the same mutation. This genetic stratifi­
cation of patients may also prove invaluable in the design 
of clinical trials aimed at primary causes. On the other 
hand, the analysis of phenotypes correlated with clinical 
states will need to look for convergence across mouse 
mutants or human patients with diverse genetic causes.
Many efforts have been made to try to identify 
equivalent characteristics between humans and rodents. 
For example, at the behavioral level, the Cognitive Neuro­
science Treatment Research to Improve Cognition in 
Schizophrenia (CNTRICS) aims to develop and imple­
ment animal model paradigms that can tap the cognitive 
and emotional­processing constructs translatable to 
humans [170]. Although only limited numbers of para­
digms are widely accepted to be translational, collabora­
tion among human neuropsychologists and animal neuro­
behavioral scientists may identify several paradigms to be 
utilized for translation. Starting these studies with animal 
models with direct etiological validity should tell us 
which behavioral constructs are really most relevant to 
human psychopathology, even if the effects manifest 
differently on the surface.
Given well­founded concerns over the species­
specificity of behavioral measures, it seems likely that 
neuro physiological measures may prove to be more 
translatable between animals and humans. This may be 
especially true of measures of functional connectivity or 
coherence between brain areas, as these may most 
powerfully index differences in network function that 
affect psychopathology. These can be assayed with EEG 
and MEG, as described above, but also with functional 
connectivity studies using functional magnetic resonance 
imaging to examine correlations between activities of 
remote but connected regions [171­174]. Although these 
measures are simply about observed correlations, they 
provide clinically relevant dynamic information that can 
be invaluable for animal studies, which can in turn 
provide more detailed mechanistic information about the 
neuronal basis of the reported aberrant connectivity. For 
example, the reduced synchrony between hippocampal 
and prefrontal regions in the 22q11.2 deletion Df(16)A+/- 
mice [105] parallels observations in humans with schizo­
phrenia [171], generating testable hypotheses about the 
origins of this defect [157]. Alterations in cortico­striatal 
or intracortical coherence in Shank3 [111], Fmr1 [122] 
and Cntnap2 mutant mice [112] similarly provide entry 
points to define the pathophysiology of these disorders at 
a level that can be directly assessed in humans, especially 
those with mutations in the same genes.
Definition of the mouse correlates of human patho­
physiology and psychopathology will also allow a reverse 
translational approach to identify new candidate suscep­
tibility genes. Prospective phenotyping of mice with 
muta tions in neurodevelopmental genes may reveal 
pheno types paralleling established models (for example, 
NogoA [175], Dlg4 [176], Sema6A [177] and Slitrk5 [178]). 
This gives a higher prior probability for assigning patho­
genicity in the event that mutations in those genes are 
then found in human patients.
Strategies towards new treatments
The drugs currently used to treat disorders like schizo­
phrenia were discovered serendipitously, are only 
partially effective for positive symptoms but not the more 
debilitating negative and cognitive symptoms, work in 
some patients and not others and have serious side effects 
[179]. For autism spectrum disorder, the situation is even 
more bleak ­ while there are some drugs prescribed to 
treat some symptoms there is no overall therapeutic of 
proven value [180]. The main reason hardly any new 
drugs (with novel mechanisms) have been successfully 
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developed in the past 60 years has been our lack of 
understanding of the underlying mechanisms of these 
disorders.
New genetic models may be utilized in identifying 
novel treatment strategies in three ways: first, to identify 
novel targets through which we can find more effective 
and safer compounds for treatment within the current 
understanding of these diseases; second, to identify novel 
targets and compounds that may not be obvious from 
current paradigms; third, and probably most important, 
to identify targets and compounds for early intervention.
By analyzing molecular, cellular and circuitry distur­
bances in new genetic models, we may find better clues 
to how the cellular pathways involving the gene of 
interest may interact with currently accepted patho­
physiological paradigms (such as the roles of GABA, 
NMDA receptors and dopamine receptors in schizo­
phrenia). In such cases, we may identify better drug 
targets, against which we can expect compounds with 
better efficacy and less side effects.
However, our hope is to identify new targets and com­
pounds with new genetic models. Although investigators 
who generate new genetic models tend to test whether 
current medications (such as clozapine and haloperidol 
for schizophrenia) can normalize deficits in behavioral 
paradigms, it may be more advantageous for new drug 
discovery to identify paradigms that are relevant to 
human diseases (that is, likely to correlate not to one 
disease but to several), but that cannot be normalized by 
current medications. For example, a DISC1 transgenic 
mouse model with neonatal poly(I:C) treatment (to mimic 
maternal infection) shows many types of behavioral 
deficit, most of which are normalized by administration 
of clozapine [181]. However, the impairment of social 
behaviors in this model is resistant to both clozapine and 
haloperidol treatment. Provided that these impairments 
are, at least in part, relevant to negative symptoms, 
screening of novel compounds to normalize this behavior 
in this model may lead to the identification of new 
treatments for negative symptoms.
Early intervention is now becoming a key in treatment 
strategies in many brain disorders, such as Alzheimer’s 
disease and schizophrenia. Animal models, especially 
those in which neurodevelopmentally important genes 
are targeted, are very useful to dissect the pathological 
course even from the premorbid stage to the full onset. 
For some symptoms, specific common phenotypes might 
be due to secondary mechanisms by which the develop­
ing brain reacts to diverse primary insults. For example, 
altered dopaminergic signaling may arise as a result of a 
variety of primary defects and may represent a final 
common pathway to psychosis [129,130,140]. The mole­
cu lar homeostatic mechanisms underlying these secon­
dary changes may thus represent a viable target for early 
intervention in genetically at­risk subjects. Similar events 
may underlie the emergence of dysfunction in other 
circuits across other disorders. In the case of schizo­
phrenia where the intervention has to occur during early 
to late adolescence, the major obstacle to moving inter­
vention to an earlier age is concerns over the effects of 
manipulating brain systems that are still developing. 
These concerns are compounded by a lack of concrete 
understanding of the biology of adolescent brain, 
especially in the context of the physiology of affect and 
cognition. Animal models will, therefore, be critical in 
advancing this aspect of the field.
A way forward
The discovery of mutations that strongly predispose 
individuals to psychopathology provides a crucial starting 
point to define pathogenic mechanisms and pathways. 
Direct animal models of genetic etiology can be analyzed 
in a comprehensive and systematic way, using the full 
arsenal of modern neuroscience to link effects on 
particular cell types in defined microcircuits to emergent 
properties of larger scale brain networks in behaviorally 
relevant contexts. These analyses will hopefully reveal 
neurobiological phenotypes that can be translated very 
directly to humans, suggest points of possible therapeutic 
intervention and aid the rational design of new drugs 
targeted at the underlying causes of mental illness.
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